MedTrace Logo

Ibuprofen Supplementation After Resistance Training and Its Effects on Bone in Older Women

NCT01886196 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-05-05

No results posted yet for this study

Summary

Inflammation increases with aging and is implicated in the reduction of bone mass, muscle mass, and strength. Resistance training is safe and effective for increasing muscle mass and strength in older adults,however resistance training by itself cannot suppress inflammation. Ibuprofen is a non-steroidal anti-inflammatory drug that may provide benefits to muscle mass and strength when given after resistance training sessions in older adults; however, more evidence is required to confirm effects across the lifespan. The objectives are to determine the effect of 9 months of exercise training and ibuprofen supplementation, compared to placebo, in older women (≥65years)on the following dependent variables:

* bone density, geometry, and architecture
* muscle mass and strength
* balance

Conditions

Interventions

DRUG

Non-steroidal anti-inflammatory drug (Ibuprofen)

400mg of ibuprofen administered after exercise training session 3 days per week

OTHER

placebo

placebo designed to mimic experimental drug (ibuprofen)

BEHAVIORAL

Resistance exercise

3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym

BEHAVIORAL

Flexibility training

3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Philip D Chilibeck, PhD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01886196 on ClinicalTrials.gov